AzTrials
AzTrials

Advanced Breast CancerPhase 3ADELANCT06382948

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

A Phase 3 study testing Everolimus, Elacestrant and Auxiliary Medicinal Product - Dexamethasone in people with Advanced Breast Cancer and ER-positive Breast Cancer, run by MedSIR at 104 sites in 9 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Everolimus, Elacestrant and Auxiliary Medicinal Product - Dexamethasone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
300 participants
Where
104 sitesin 9 countries
Study dates
5 Dec 2024to Apr 2028
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients will be included in the study only if they meet ALL of the following criteria:
  • Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.
  • Female or male patients ≥ 18 years of age at the time of signing ICF.
  • Pre- or perimenopausal women, who do not meet the criteria for post-menopausal status (defined in continuation) and men must be concurrently receiving a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/follicle-stimulating hormone [FSH] must be confirmed analytically) prior to study randomization and are planning to continue LHRH agonist treatment during the study.
  • Post-menopausal women as defined by any of the following criteria:
  • Age ≥ 60 years;
Show all 31Show fewer
  • Age < 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH levels within the laboratory's reference range for post-menopausal females;
  • Documented bilateral surgical oophorectomy.
  • Histologically- or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either unresectable locally recurrent or metastatic disease confirmed by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent.
  • Documentation of ER[+] (≥10% positive stained cells) and HER2[-] (0-1+ by immunohistochemistry [IHC] or 2+ and negative by in situ hybridization [ISH] test) tumor according to the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as per local assessment. ER[+]/HER2[-] status should be confirmed in metastatic setting, with exception of patients with bone and lung only disease.
  • Patients with ESR1 mutational status will be determined before patient randomization using Guardant360 CDx (Guardant Health) test.
  • Note: Patients with previously determined ESR1 mutation using appropriately validated tests (Guardant360 CDx [Guardant Health], FoundationOne CDx, FoundationOne Liquid [Foundation Medicine Inc]) will be eligible for inclusion. This local determination can be performed either in blood or tumor samples.
  • Radiological or objective evidence of disease progression on prior treatment with a CDK4/6 inhibitor in combination with endocrine therapy for advanced disease after at least 6 months of treatment. Patients receiving CDK4/6 inhibitor-based therapy in the adjuvant setting are also eligible provided that disease progression is confirmed after at least 12 months of treatment but no more than 12 months following CDK4/6 inhibitor treatment completion in this scenario.
  • Patients must have previously received at least one and no more than two lines of endocrine therapy for ABC. Progression during or within 12 months of adjuvant endocrine therapy is considered as a line of endocrine therapy for advanced disease.
  • No prior elacestrant or other investigational SERDs, proteolysis targeting chimera (PROTAC), complete estrogen receptor antagonist (CERAN), or novel SERM, and/or PI3K/AKT/mTOR inhibitors, including everolimus, for advanced disease are permitted.
  • Note: Fulvestrant is permitted if treatment was completed administered at least 28 days before randomization.
  • No prior chemotherapy for advanced disease is allowed.
  • Evidence of measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1), or non-measurable, but evaluable, disease, including bone-only disease with at least one lytic or mixed lytic-blastic bone lesion.
  • Willingness and ability to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue or block. If a newly obtained baseline biopsy of an accessible tumor lesion is not possible to be obtained prior randomization, an archival tissue sample will be accepted.
  • Fasting serum cholesterol ≤ 300 mg/dL or 7.75 mmol/L and fasting triglycerides ≤ 2.5 times the upper limit of normal (x ULN).
  • Adequate bone marrow and organ function:
  • Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within seven days before randomization): absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100.0 x109/L; and hemoglobin ≥ 9.0 g/dL.
  • Hepatic: Serum albumin ≥ 2.5 g/dL; total serum bilirubin < 1.5 x ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN; alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 3 x ULN in patients with liver and/or bone metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 x ULN (≤ 3 x ULN in patients with liver metastases).
  • Renal: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as calculated by Cockcroft- Gault equation.
  • Coagulation: International normalized ratio (INR) ≤ 1.5 x ULN, unless that the patient meets the exception described in the exclusion criteria 16.
  • Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 (except for toxicities not considered a safety risk for the patient at Investigator's discretion).
  • Note: Patients with grade 2 alopecia are allowed.
  • Women of childbearing potential who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 7 days before randomization. In addition, they agree to use one highly effective method of birth control 28 days prior to start of treatment until 120 days after the last dose of study treatments. Female patients must refrain from egg cell donation and breastfeeding during this same time period.
  • Male participants with a female partner of childbearing potential must be surgically sterile or using a highly effective method of contraception 28 days prior to treatment until 120 days after the last dose of study treatments to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and 120 days after the last dose of study treatments is an acceptable practice if this is the preferred usual lifestyle of the participant.
  • ECOG performance status of 0-1.
  • Minimum life expectancy of ≥ 12 weeks at screening.

Who cannot join

  • Any patient meeting ANY of the following criteria will be excluded from the study:
  • Inability to comply with study and follow-up procedures.
  • Formal contraindication to endocrine therapy defined as visceral crisis and/or rapidly or symptomatic progressive visceral disease.
  • Current participation in another therapeutic clinical trial.
  • Treatment with approved or investigational cancer therapy within 14 days prior to randomization except for fulvestrant that must be administered completed at least 28 days before randomization.
  • Known active uncontrolled or symptomatic central nervous system (CNS) metastases and/or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases are eligible if they have been previously treated with local therapy, are clinically stable, and off anticonvulsants and steroids for at least 14 days before randomization.
Show all 29Show fewer
  • Intact uterus with a history of endometrial intraepithelial neoplasia (atypical endometrial hyperplasia or higher-grade lesion).
  • Concurrent malignancy or malignancy within three years before randomization with the exception of carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.
  • Known allergy or hypersensitivity reaction to any investigational medicinal products (IMPs) or their incorporated substances.
  • History of malabsorption syndrome or other condition that would interfere with enteral absorption (ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass) or results in the inability or unwillingness to swallow pills.
  • Palliative radiotherapy with a limited field of radiation within two weeks or with wide field of radiation or to more than 30% of the bone marrow within four weeks prior to randomization.
  • Major surgical procedure or significant traumatic injury within 14 days before randomization or anticipation of need for major surgery within the course of the study treatment.
  • Clinically relevant cardiovascular/cerebrovascular disease and/or cardiac dysfunction or conduction abnormalities including, but not confined, to any of the following:
  • Symptomatic pericarditis, unstable angina pectoris, documented myocardial infarction, coronary/peripheral artery bypass graft, symptomatic cardiac heart failure (CHF) (New York Heart Association [NYHA] Class II-IV), or cerebrovascular accident including transient ischemic attack within six months before study randomization.
  • Concurrent uncontrolled atrial fibrillation, other ongoing cardiac dysrhythmias grade ≥ 2 as determined by NCI-CTCAE v.5.0, or prolonged QT Interval Corrected by Fridericia's formula ([QTcF] > 480 msec).
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited, to any of the following:
  • Massive lung metastatic involvement (e.g., pleural effusion, lymphangitic carcinomatosis, etc.).
  • Any underlying pulmonary disorder (e.g., severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, post Coronavirus disease (COVID-19) pulmonary fibrosis, etc.).
  • Any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.).
  • Prior pneumonectomy.
  • History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • Coagulopathy or any history of coagulopathy within six months before study enrollment, including history of deep vein thrombosis or pulmonary embolism. However, patients with the following conditions will be allowed to participate:
  • Adequately treated catheter-related venous thrombosis occurring more than 28 days prior to randomization.
  • Treatment with an anticoagulant (e.g., warfarin or heparin) for a thrombotic event occurring more than six months before randomization, or for an otherwise stable and allowed medical condition (e.g., well controlled atrial fibrillation), provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to randomization.
  • Concomitant treatment with immunosuppressive agents or chronic corticosteroids use before randomization with the following exceptions: topical applications, inhaled sprays, eye drops, mouthwash, or local injections are allowed. Patients on stable low dose of corticosteroids ( ≤ 10 mg/day of prednisone or equivalent) for at least two weeks before randomization are also permitted.
  • Unable or unwilling to avoid prescription medications, over-the-counter medications, dietary/herbal supplements (e.g., St. John's wort), and/or foods (e.g., grapefruit, pomelos, star fruit, Seville oranges and their juices) that are moderate/strong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, and/or foods are discontinued for at least five half-lives or 14 days (whichever is shorter) prior to randomization and for the duration of the study.
  • Pregnant or lactating women or patients not willing to apply highly effective contraception as defined in the protocol.
  • Current known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. Any other active uncontrolled infection at the time of screening is not allowed.
  • Known substance abuse or any other concurrent severe and/or uncontrolled psychiatric or medical condition that would, in the Investigator's judgment, contraindicate patient participation.

Trial locations and contacts

104 sites in 9 countries. Contact the study team or a site near you to ask about taking part.

Medsir contact

+34932214135

contact.trials@medsir.org

104 sites in 9 countries

Spain42 sites, 41 recruiting

  • Centro Oncológico de Galicia

    A Coruña

    Pablo Alvarez, MD

    Recruiting

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    A Coruña

    Juan Cueva, MD

    Recruiting

  • Hospital General Universitario Dr. Balmis (Alicante)

    Alicante

    Jose Ponce Lorenzo, MD

    Recruiting

  • Hospital Universitario San Juan de Alicante

    Alicante

    Nieves Diaz, MD

    Recruiting

  • Institut Català d' Oncologia Badalona (ICO)

    Badalona

    Laia Boronat, MD

    Recruiting

  • Hospital Universitari Dexeus

    Barcelona, Barcelona

    Laia Garrigós, MD

    Recruiting

  • Hospital Clínic i Provincial de Barcelona

    Barcelona

    Isabel García, MD

    Recruiting

  • Hospital del Mar

    Barcelona

    Sonia Servitja, MD

    Recruiting

  • Hospital Universitari Vall D'Hebron

    Barcelona

    Esther Zamora, MD

    Recruiting

  • Hospital Universitario de Basurto

    Bilbao

    Elena Galve, MD

    Recruiting

  • Hospital Universitario de Burgos

    Burgos

    Blanca Hernando, MD

    Recruiting

  • Hospital San Pedro de Alcántara

    Cáceres

    Santiago González, MD

    Recruiting

  • Hospital Provincial de Castellón

    Castellon

    Eduardo Martínez, MD

    Recruiting

  • Hospital Universitario de Elche

    Elche

    Alvaro Rodriguez, MD

    Recruiting

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada

    Isabel Blancas, MD

    Recruiting

  • Complejo Hospitalario de Jaén

    Jaén

    Rocio Urbano, MD

    Recruiting

  • Hospital Universitario Insular de Gran Canaria

    Las Palmas de Gran Canaria

    Elisenda Llabres, MD

    Recruiting

  • Hospital Universitario de León

    León

    Mariana López, MD

    Recruiting

  • Hospital Universitario Arnau de Vilanova de Lleida

    Lleida

    Serafin Morales, MD

    Recruiting

  • Hospital Beata María Ana

    Madrid

    Cristina Saavedra, MD

    Recruiting

  • Hospital San Carlos

    Madrid

    Jose Angel Garcia Saenz, MD

    Recruiting

  • Hospital Universitario Doce de Octubre

    Madrid

    Pablo Tolosa, MD

    Recruiting

  • Hospital Universitario La Paz

    Madrid

    Virginia Martinez, MD

    Recruiting

  • Hospital Universitario Puerta de Hierro Majadahonda

    Madrid

    Blanca Cantos, MD

    Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid

    Alfonso Cortes, MD

    Recruiting

  • Hospital Universitario Sanchinarro-START-CIOCC

    Madrid

    Raquel Bratos, MD

    Recruiting

  • MD Anderson Cancer Center Madrid

    Madrid

    Laura Garcia, MD

    Recruiting

  • Fundacion Althaia

    Manresa

    Clara Martinez Vila, MD

    Recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia

    Jose Luis Alonso, MD

    Recruiting

  • Hospital Universitari Son Espases

    Palma de Mallorca

    Antonia Perelló, MD

    Recruiting

  • Hospitalario Universitario de Navarra

    Pamplona

    Susana Cruz, MD

    Recruiting

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife

    Josefina Cruz, MD

    Recruiting

  • Hospital Quirónsalud Sagrado Corazón

    Seville

    María Valero, MD

    Recruiting

  • Hospital Universitario Virgen del Rocío

    Seville

    Manuel Ruiz, MD

    Recruiting

  • Hospital Universitario Virgen Macarena

    Seville

    Luis Cruz, MD

    Recruiting

  • Hospital Universitari Sant Joan de Reus

    Tarragona

    Alba Cochs, MD

    Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Valdecilla

    Carmen Hinojo, MD

    Recruiting

  • Consorci Hospital General Universitari de València

    Valencia

    Vega Iranzo, MD

    Recruiting

  • Hospital Arnau de Vilanova de Valencia

    Valencia

    Active, not recruiting

  • Hospital Clínico Universitario de Valencia

    Valencia

    Begoña Bermejo, MD

    Recruiting

  • Hospital Universitario La Ribera - Alzira

    Valencia

    Athanasios Pouptsis, MD

    Recruiting

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza

    Raquel Andres, MD

    Recruiting

Other trials in Spain

France12 sites, 12 recruiting

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeau

    Nadine Dohollou, MD

    Recruiting

  • Institut Bergonié Bordeaux

    Bordeaux

    Monica Arnedos, MD

    Not yet recruiting

  • Centre Georges François Leclerc

    Dijon

    Sylvain Ladoire, MD

    Recruiting

  • Centre Hospitalier de Limoges

    Limoges

    Monica Arnedos, MD

    Recruiting

  • CHU Lyon Sud

    Lyon

    Gilles Freyer, MD

    Recruiting

  • Institut Paoli Calmettes

    Marseille

    Alexandre Tassin de Nonneville, MD

    Not yet recruiting

  • APHP Tenon

    Paris

    Joseph Gligorov, MD

    Not yet recruiting

  • Hospital prive des Cotes d'Amor

    Plérin

    Anne Claire Hardy-Bessard

    Recruiting

  • CHU Saint Etienne

    Saint-Priest-en-Jarez

    Gilles Freyer, MD

    Recruiting

  • Centre Paul Strauss

    Strasbourg

    Thierry Petit, MD

    Recruiting

  • IUCT Oncopole

    Toulouse

    Florence Dalenc, MD

    Recruiting

  • Institute de Cancerologie de Lorraine - Nancy

    Vandœuvre-lès-Nancy

    Vincent Massard, MD

    Recruiting

Other trials in France

Italy12 sites, 12 recruiting

  • Cliniche Gavazzeni

    Bergamo

    Fabio Conforti, MD

    Not yet recruiting

  • Azienda Ospedaliero-Universitaria (AOU) di Cagliari

    Cagliari

    Mario Scartozzi, MD

    Not yet recruiting

  • Aou Careggi

    Florence

    Icro Meattini, MD

    Recruiting

  • IRCCS Ospedale Policlinico San Martino

    Genova

    Lucia del Mestro, MD

    Not yet recruiting

  • Ospedali Riuniti Livorno

    Livorno

    Giacomo Allegrini, MD

    Recruiting

  • Instituto Europeo di Oncologia

    Milan

    Carmen Criscitiello, MD

    Recruiting

  • AOU Policilinico Modena

    Modena

    Federico Piacentini, MD

    Recruiting

  • IRCCS San Gerardo

    Monza

    Marina Cazzaniga, MD

    Not yet recruiting

  • Fondazione Pascale

    Naples

    Michelino di Laurentis, MD

    Not yet recruiting

  • Azienda Ospedaliero- Universitaria Maggiore Della Carita

    Novara

    Alessandra Gennari, MD

    Recruiting

  • Oncologia Medica AUSL Piacenza

    Piacenza

    Serena Madaro, MD

    Recruiting

  • Policlinico A. Gemelli IRCCS

    Roma

    Ida Paris, MD

    Not yet recruiting

Other trials in Italy

Greece10 sites, 10 recruiting

  • University General Hospital Alexandroupoli

    Alexandroupoli

    Dimitros Matthaios, MD

    Recruiting

  • 251 Air Force General Hospital

    Athens

    Vasileios Ramfidis, MD

    Recruiting

  • Aretaeio Hospital

    Athens

    FLORA ZAGOURI, MD

    Recruiting

  • Attikon University Hospital

    Athens

    Amanda Psyrri, MD

    Recruiting

  • Metropolitan General Hospital 4th department

    Athens

    Helena Linardou, MD

    Recruiting

  • University General Hospital of Heraklion

    Heraklion

    Dimitrios Mavroudis, MD

    Recruiting

  • University General Hospital of Larissa

    Larissa

    Athanasios Kotsakis, MD

    Recruiting

  • General University Hospital of Patras

    Pátrai

    Athina Christopoulou, MD

    Recruiting

  • Metropolitan Hospital Greece 1st department

    Piraeus

    Dimitrios Bafaloukos, MD

    Recruiting

  • EU Interbalkan Medical Center

    Thessaloniki

    Konstantinos Papazisis, MD

    Recruiting

Other trials in Greece

Germany7 sites, 7 recruiting

  • MVZ Klinikum Aschaffenburg

    Aschaffenburg

    Manfred Welslau, MD

    Not yet recruiting

  • Hämatologie-Onkologie im Zentrum MVZ GmbH

    Augsburg

    Bernhard Heinrich, MD

    Not yet recruiting

  • Städtisches Klinikum Dessau

    Dessau

    Herrmann Voß, MD

    Not yet recruiting

  • Universitätsklinikum Dusseldorf

    Düsseldorf

    Eugen Ruckhäberle, MD

    Not yet recruiting

  • Universitätsklinikum Essen

    Essen

    Anja Welt, MD

    Not yet recruiting

  • MVZ II der Niels Stensen Kliniken

    Georgsmarienhütte

    Kerstin Luedtke-Heckenkamp, MD

    Recruiting

  • Klinikum Worms - Frauenklinik

    Worms

    Sebastian Züfle, MD

    Recruiting

Other trials in Germany

Czechia6 sites, 6 recruiting

  • Masaryk Memorial Cancer Institute

    Brno

    Milos Holanek, MD

    Recruiting

  • Multiscan Nemocnice Horovice

    Hořovice

    Martin Smakal, MD

    Recruiting

  • University Hospital Olomouc

    Olomouc

    Bohuslav Melichar, MD

    Not yet recruiting

  • General University Hospital Prague

    Prague

    Martina Zimovjanova, MD

    Recruiting

  • Motol University Hospital

    Prague

    Adela Danesh

    Recruiting

  • Tomas Bata Regional Hospital in Zlin

    Zlín

    Michaela Zábojníková, MD

    Recruiting

Other trials in Czechia

United Kingdom6 sites, 6 recruiting

  • Western General Hospital

    Edinburgh

    Olga Oikonomidou, MD

    Not yet recruiting

  • Barts Health NHS Trust

    London

    Peter Schmid, MD

    Recruiting

  • Genesis Care Oxford

    Oxford

    Mark Tthill, MD

    Recruiting

  • Royal Surrey County Hospital

    Surrey Quays

    Felicity Paterson, MD

    Recruiting

  • Royal Cornwall Hospital NHS Trust

    Truro

    Alastair Thomson, MD

    Recruiting

  • Genesis Cancer Care UK

    Waterlooville

    Mark Tuthill, MD

    Recruiting

Other trials in United Kingdom

Brazil5 sites, 5 recruiting

  • Tacchini Instituto de Pesquisa

    Bento Gonçalves

    Andrea Borba, MD

    Not yet recruiting

  • Hospital Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim

    Sabina Aleixo, MD

    Not yet recruiting

  • Catarina Pesquisa Clínica - Neoplasias Litoral

    Itajaí

    Giuliano Borges, MD

    Not yet recruiting

  • UPCO - Hospital de Clinicas de Porto Alegre

    Porto Alegre

    Carlos Barrios, MD

    Not yet recruiting

  • NOB Ondina

    Salvador

    Lucia Landero, MD

    Not yet recruiting

Other trials in Brazil

Austria4 sites, 4 recruiting

  • Medizinische Universität Innsbruck

    Innsbruck

    Daniel Egle, MD

    Recruiting

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz

    Clemens Dormann, MD

    Recruiting

  • Ordination Priv.-Doz. Dr. Michael Hubalek

    Schwaz

    Michael Hubalek, MD

    Recruiting

  • Medical University of Vienna

    Vienna

    Rupert Bartsch, MD

    Not yet recruiting

Other trials in Austria

About this study

Official title: A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors

This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.

The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival.

Rigorous eligibility criteria based on specific co-morbidities and clinicopathologic features of their disease have been designed to minimize the risk of patients participating in this study. The anticipated favorable clinical benefits of elacestrant combined with everolimus are projected to outweigh the risks of this treatment. This study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

Read the detailed description

Upon meeting all selection criteria, a total of 300 patients will be enrolled.

After signing the Informed Consent Form (ICF), patients will be randomized (ratio 1:1) as follows:

  • Interventional Arm (Arm A) (N=150): Patients will receive 345 mg of elacestrant and 7.5 mg of everolimus orally once daily.
  • Control Arm (Arm B) (N=150): Patients will receive elacestrant at 345 mg orally once daily plus everolimus placebo.

Patients will be stratified by presence of visceral metastases (yes versus no) and duration of prior CDK4/6 inhibitor-based therapy (≥ 12 months versus < 12 months). Patients progressing to CDK4/6 inhibitor-based therapy in the adjuvant setting will be stratified as patients with a duration of prior CDK4/6 inhibitor-based therapy < 12 months.

Patients will receive study treatment in 28-day cycles until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.

Patients discontinuing the study treatment period will enter a post-treatment follow-up period during which survival and new anti-cancer therapy information will be collected every 3 months (± 14 days) from the last dose of IMPs until the End of Study (EoS) defined as 12 months after last patient is randomized unless premature termination of the trial. For patients who discontinue the study treatment for reasons other than disease progression, tumor assessments will be conducted following the frequency of the study until the start of a new anti-cancer treatment, death, or disease progression.

Being tested
Everolimus, Elacestrant, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
Keywords
ER-positive, HER22-negative, ESR1-mutation, CDK4/6-inhibitor, Selective endocrine receptor degrader (SERD)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EverolimusDrug

    Also called Zortress, Votubia, RAD001, Certican

    Patients will receive 7.5 mg of everolimus orally once daily.

  • ElacestrantDrug

    Also called ER-306323, RAD1901, Selective estrogen receptor degrader/selective estrogen receptor modulator (SERD/SERM) RAD1901

    Patients will receive elacestrant 345 mg orally once daily

  • PlaceboDrug

    Patients will receive placebo orally once daily

  • Auxiliary Medicinal Product - DexamethasoneDrug

    10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.

  • Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analoguesDrug

    According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.

Study groups in NCT06382948
Study groupRoleWhat they receive
Interventional Arm 1ExperimentalPatients will receive 345 mg of elacestrant and 7.5 mg of everolimus orally once daily. Patients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first.
Receives: Drug: Everolimus; Drug: Elacestrant; Drug: Auxiliary Medicinal Product - Dexamethasone; Drug: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
Control Arm 2Active comparatorPatients will receive elacestrant at (345 mg orally once daily) plus matched everolimus placebo. Patients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first.
Receives: Drug: Elacestrant; Drug: Placebo; Drug: Auxiliary Medicinal Product - Dexamethasone; Drug: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).

    Progression Free Survival (PFS), defined as the period from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first, as assessed by a Blinded Imaging Review Committee (BIRC) through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

Secondary outcomes (17)

  1. To compare overall survival (OS) between treatment groups, in all patients.

    OS, defined as the period from randomization to death from any cause, as determined locally by the Investigator.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  2. To compare investigator-assessed PFS based on local assessment between treatment groups, in all patients.

    Investigator-assessed PFS, defined as the period from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined locally using RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  3. To compare objective response rate (ORR) between treatment groups, in all patients.

    ORR is defined as the rate of patients with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) based on a BIRC and local Investigator assessment through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  4. To compare clinical benefit rate (CBR) between treatment groups, in all patients.

    CBR is defined as the rate of patients with an objective response (CR or PR), or stable disease for at least 24 weeks based on a BIRC and local Investigator assessment through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  5. To compare overall time to response (TTR) between treatment groups, in all patients.

    TTR is defined as the period from the randomization to time of the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a BOR of CR or PR based on a BIRC and local Investigator assessment through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  6. To compare duration of response (DoR) between treatment groups, in all patients.

    DoR is defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, based on a BIRC and local Investigator assessment through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  7. To compare best percentage of change in tumor burden between treatment groups, in all patients.

    Best percentage of change from baseline in the size of target tumor lesions is defined as the biggest decrease, or smallest increase if no decrease will be observed, based on a BIRC and local Investigator assessment through the use of RECIST v.1.1.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  8. To describe the changes in health-related quality-of-life (HRQoL) from baseline using the EuroQoL 5 Dimension 5 Level (EQ-5D-5L) scale.

    Changes from baseline in the EQ-5D-5L scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels, indicating, from 1 to 5: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  9. To describe the changes in HRQoL from baseline using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

    Changes from baseline in the EORTC QLQ-C30 scale. All of the scales and single item measures range in score from 0 to 100. A high score for the functional scales and functional single items represents a high/healthy level of functioning, whereas a high score for the symptom scales and symptom item represents a high level of symptomatology or problems.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  10. To describe the changes in HRQoL from baseline using the EORTC Quality of Life Questionnaire Breast Cancer module (EORTC QLQ-BR42).

    Changes from baseline in the QLQ-BR42 scale. All of the scales and single item measures range in score from 0 to 100. A high score for the functional scales and functional single items represents a high/healthy level of functioning, whereas a high score for the symptom scales and symptom item represents a high level of symptomatology or problems.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  11. To assess adverse events (AEs) between treatment groups in all patients.

    Measures will include AEs and treatment-emergent AEs (TEAEs), including NCI CTCAE v5.0 severity grade and relationship to study drugs.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  12. To assess adverse events leading to study treatment withdrawal.

    Measures will include deaths, serious adverse events (SAEs), and AEs leading to study treatment withdrawal.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  13. To assess adverse events leading to dose modification.

    Measures will include dose interruption and reductions due to AEs.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  14. To assess the number of participants with abnormal hematology and/or chemistry values that are related to treatment.

    Number of participants with treatment-related AEs as measured by laboratory parameters (hematology and chemistry) and assessed by NCI CTCAE v5.0 grade.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  15. To assess the number of participants with changes on vital signs and/or AEs that are related to treatment.

    Number of participants with treatment-related changes on vital sign values as determined by respiratory rate, blood pressure (systolic and diastolic), pulse rate, and body temperature over time and assessed by NCI-CTCAE v.5.0.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  16. To assess the number of participants with changes on cardiac function measured by ECG QT Interval Corrected by Fridericia formula (QTcF) that are related to treatment effect .

    Measurement of treatment-related changes in cardiac function measured by ECG QTcF over time.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

  17. To assess the number of participants with changes on Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) that are related to treatment.

    Measurement of treatment-related changes on patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.), as measured with the ECOG PS scale over time.

    Measured: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2024
  2. Study start5 Dec 2024
  3. Primary completionSep 2027 (estimated)
  4. Study completionApr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double-blind, parallel group (two arms: elacestrant plus everolimus, and elacestrant plus placebo).
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06382948
Sponsor's protocol ID
MedOPP545
Other IDs
2024-512926-27-00
Acronym
ADELA
Status last verified
Aug 2026
First submitted
5 Apr 2024
Last updated
24 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Perez-Garcia JM, Llombart-Cussac A, Lopez-Miranda E, Cortes A, Garcia I, Galve-Calvo E, Ruiz-Borrego M, Cochs A, Perello-Martorell A, Morales S, Boronat Ruiz L, Marin-Liebana S, Saavedra C, Blancas I, Hinojo C, Lopez Flores M, Ladoire S, Schmid P, Freyer G, Rui Zhang R, Alcala-Lopez D, Carvalho-Santos J, Boix O, Barrios CH, Curigliano G, Bartsch R, Hardy Bessard AC, Wasserman T, Cortes J. Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor. Future Oncol. 2026 Oct 31:1-13. doi: 10.1080/14796694.2026.2753794. Online ahead of print.

    PubMed 42965829

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Everolimus, Elacestrant and Auxiliary Medicinal Product - Dexamethasone in people with Advanced Breast Cancer and ER-positive Breast Cancer, run by MedSIR at 104 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 31 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 104 sites in Spain, France, Italy, Greece, Germany and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Medsir (+34932214135, contact.trials@medsir.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients). (time frame: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06382948, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in